Reported 4 days ago
Pfizer's stock presents a potentially lucrative opportunity as it experiences recovery post-pandemic, driven by growth in specialty care and oncology. Despite a significant decline in stock value, Pfizer's financial stability is underscored by a strong dividend yield of 6.3%, and management's commitment to maintain and increase this dividend. With projected earnings growth of 10% to 18% for 2025, investors could see solid returns, making it an appealing time to consider investing in Pfizer.
Source: YAHOO